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Abstract
Objective
To assess the effect of administering an oral dose of 2g of azithromycin in Gambian women
during labour on infant growth.
Methods
Children whose mothers had been randomized to receive either an oral dose of 2g of azi-
thromycin or placebo during labour were visited at home at the end of infancy by trained
study nurses blind to the treatment allocation. The follow-up visit of these cohorts (exposed
and non-exposed to azithromycin), which was not part of the original trial design, was con-
ducted between November 2014 and May 2015 when the infants were 11 to 13 months of
age. During visits, nurses recorded anthropometrical measurements and transcribed infor-
mation from the infants’ welfare cards.
Results
Four-hundred and sixty-five (79.6%) of the 584 infants aged 11–13 months at the time of the
survey were recruited. The proportion of children with an age-adjusted Z-score <-2SD for
mid-upper-arm circumference (MUAC) was lower among those exposed to azithromycin
[1.3% versus 6.3%, OR = 0.21 95%CI (0.06,0.72), p = 0.006] and there was weak evidence
of a difference in the proportion of infants with weight-for-age (WAZ) Z-score <-2SD [7.1%
versus 12.1%, OR = 0.58 95%CI (0.33,1.04), p = 0.065]. For all other malnutrition indicators
the proportions were similar in the exposed and un-exposed cohort.
Conclusions
Our results show that azithromycin in labour may have a beneficial effect in MUAC among
children who are below the curve. Larger studies with closer follow-up are warranted.
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Introduction
Azithromycin is a broad spectrum antibiotic used to treat infectious diseases such as pneumo-
nia, middle ear infections, chlamydia, gonorrhoea and malaria. It has also been used in mass
drug administration (MDA) campaigns to control trachoma [1]. Such campaigns have
reported beneficial effects beyond the target disease. In Ethiopia, MDA with azithromycin for
trachoma control reduced all-cause mortality in 1–9 years old children by 49% [2] and in The
Gambia MDA reduced asymptomatic pneumococcal carriage [3]. While the mechanism
underlying the mortality reduction reported in Ethiopia was not clear, Porco et al suggested
that it may have been due to an improvement in nutritional status among children who
received azithromycin [2]. A subsequent systematic review of the association between antibi-
otic use and growth found that antibiotic use promotes linear growth and weight gain in chil-
dren in low and middle-income countries [4], where the prevalence of malnutrition in
children is high. The hypothesis is also supported by data from randomized clinical trials using
azithromycin and anti-malarial drugs during pregnancy, which have shown that this combina-
tion increases birth weight [5–7] and reduced the incidence of stunting in childhood [8].
We recently conducted a trial in Western Gambia in which women in labour were random-
ized to receive oral azithromycin or placebo [9]. The primary outcome of the trial was neonatal
nasopharyngeal carriage of Staphylococcus aureus, Group B Streptococcus or Streptococcus
pneumoniae. Maternal bacterial carriage in the nasopharynx, breast milk and low vaginal tract
were also assessed. Prevalence of carriage of study bacteria was lower in the first month after
birth in mothers who had received azithromycin and their newborns [10]. In addition, fewer
episodes of maternal and neonatal illness were reported in the azithromycin arm during the 8
weeks of follow-up [11].
We conducted a follow up visit of children at 1 year of age, to compare child growth
between those who were exposed to azithromycin (because the mother received azithromycin
during labour) and those who were not exposed. Our hypothesis was that by reducing bacterial
carriage during early life, azithromycin would reduce malnutrition, a major risk factor for
child mortality [12].
Methods
Study site and population
The study was based at the Jammeh Foundation for Peace (JFP), a government-run health cen-
tre located in Western Gambia that manages 4,500 deliveries per year [10]. The population
covers the main ethnic groups in The Gambia and illiteracy is high. The climate of the area is
typical of the sub-Sahel region.
Main trial
The study protocol has been described elsewhere [9]. Briefly, this was a phase-III, double-
blind, placebo-controlled trial in which 829 pregnant women attending the labour ward
in JFP were randomized to receive a single oral dose of 2g of either oral azithromycin or
placebo (ratio 1:1). The primary endpoint of the trial was prevalence of S. aureus, GBS or
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S. pneumoniae carriage in the NPS sample of the newborn at day 6 and secondary end-
points included disease and hospitalization in women and newborns during the 8 weeks
of follow up. Secondary analysis included estimating the effect of the intervention on clin-
ical disease during the 8 weeks of follow-up [11]. The trial started in April 2013 and lasted
14 months.
The packaging and labeling of the investigational medicinal product (IMP) was con-
ducted byIdifarma. Azithromycin and placebo were provided as tablets packed in blisters.
One blister pack of IMP contained 4 tablets of 0.5g (2g) of either azithromycin or pla-
cebo. The randomisation list was created by an independent data manager and Idifarma
numbered the blisters according to the list [9]. The active drug and the placebo looked
identical.
Follow-up visit during infancy
Between November 2014 and May 2015, a follow-up visit at home was conducted for children
aged 11–13 months whose mothers had been randomized to receive either an oral dose of 2g
of azithromycin (exposed) or placebo (non-exposed). These children were visited at home by a
trained nurse blind to the treatment allocation and anthropometric measurements were
recorded. Children were weighed on a standard calibrated scale (Tanita scale) which measures
to a precision of 0.1kg. Height was measured using a standard calibrated length board with a
precision of 0.1cm. We used a standard coloured and gradated tape to measure mid-upper-
arm circumference (MUAC) and a suitable measuring tape for the head circumference, both
with a precision of 0.1cm. During the visits, the nurse also transcribed height and weight mea-
surements from the infant’s health card onto the study questionnaire.
Ethical approval
Both the main trial and the adhoc follow up visit were approved by the Joint MRC/Gambia
Government Ethics Committee. Mothers of children participating in the survey signed an
additional informed consent.
Statistical analysis
Study questionnaires were reviewed before being double entered into OpenClinica (www.
openclinica.com). We used WHO child-growth standards to calculate Z-scores for height-for-
age (HAZ), weight-for-age (WAZ), weight-for-height (WHZ), body mass index-for-age, head
circumference-for-age, and MUAC for age [WHO Anthro version 3.2.2, January 2011]. Chil-
dren with z-scores <-2SD and <-3SD were classified as malnourished and severely-malnour-
ished, respectively [13]. For each score, we used risk ratios and Fisher’s exact test to compare
the proportion with a Z-score<-2 SD and<-3SD between the study arms. In addition, we
used weight measurements transcribed from the welfare-card and measurements taken at 12
months to estimate growth curves (0–12 months) for children in each trial arm. The curves
were estimated by fitting a spline function to the weight data using random effects linear
regression. No other covariates were included in the regression. The standardized residuals
obtained from fitting these models were compared between arms (residuals were standardized
by dividing by the standard deviation of the residuals). Specifically, we compared the propor-
tion of standardized residuals<-2 SD using logistic regression, with cluster-robust variance
estimates. We used a p-value cut-off of 0.05 to define statistical significance. Analyses were
done using Stata version 14.1.
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Results
Study profile
In the trial, 829 women were recruited during labour, and 830 children were born alive, of
whom 814 survived until the end of the 8-week follow-up period. Out of 814 children alive at
8-weeks, 5 had died and 196 were>13 months at the time of the survey. Among the 613 study
children�13 months of age at the time of starting the long-term survey, 465 (76.0% of 613
and 57% of the 814) participated in the follow up visit (S1 Fig). Characteristics of study partici-
pants and non-participants are shown in Table 1.
Baseline characteristics (age at follow up, gender, ethnic group, season at birth, birth weight
and maternal age) of children in the azithromycin (n = 226) and the placebo group (n = 239)
were similar, except for the higher number of multiple pregnancies in the placebo group
(p = 0.037) (Table 2).
Growth curves
The growth curves were estimated from n = 1,575 measurements in the placebo group (6.6 per
child) and 1,472 measurements (6.5 per child) in the placebo group. The curves were similar
for both cohorts of children (S2 Fig). The proportion of standardized residuals <-2SD was also
similar in both groups [1.8% versus 3.1%, adjusted OR = 0.59 95% CI (0.22,1.59)].
12 months follow-up visit
The proportion with MUAC-for-age<-2SD was significantly lower in the azithromycin group
[1.3% versus 6.3%, RR = 0.21 95% CI (0.06,0.72)] (Table 3). For all other anthropometrical
measures the proportions were similar in both groups.
Proxy signs for nutritional status were similar between groups (Table 4).
Between the end of the trial (8 weeks) and the follow up home visit, 3 children in the azi-
thromycin and 7 children in the placebo groups had records of hospitalization.
Table 1. Characteristics of study participants who participated and not in the long term follow-up visit.
Variables Categories 12 months survey included (N = 465)
n/N (%)
12 months survey not included (N = 378)
n (%)
p-value
Sex Female 230 (49.5) 175 (46.3) 0.360
Male 235 (50.5) 203 (53.7)
Ethnicity Mandinka 201 (43.5) 151 (41.8) 0.367
Wollof 49 (10.6) 45 (12.5)
Jola 80 (17.3) 47 (13.0)
Fula 76 (16.5) 68 (18.8)
Other 56 (12.1) 50 (13.9)
Maternal
schooling
<1 year 231 (49.9) 193 (53.8) 0.271
� 1 year 232 (50.1) 166 (46.2)
Maternal age 18–19 years 30 (6.5) 37 (9.8) 0.109
20–29 years 295 (63.4) 244 (64.6)
�30 years 140 (30.1) 97 (25.7)
Multiple
pregnancy
No 453 (97.4) 362 (95.8) 0.183
Yes 12 (2.6) 16 (4.2)
Low birth
weight (<2.5kg)
No 432 (93.1) 354 (93.9) 0.642
Yes 32 (6.9) 23 (6.1)
https://doi.org/10.1371/journal.pone.0206348.t001
Impact of azithromycin given in labour on infant nutrition
PLOS ONE | https://doi.org/10.1371/journal.pone.0206348 October 25, 2018 4 / 9
Discussion
Children born to mothers treated with oral azithromycin during labour were less likely to have
MUAC standardized z-score<2SD at around 1 year of age, although the mean MUAC was
similar in the two study groups. It is also encouraging that the proportion of undernourished
infants (<2SD for WAZ, HAZ, BMI, WHZ and MUAC) appears to be lower in the azithromy-
cin arm, but these findings are not conclusive because only the difference in MUAC was statis-
tically significant.
Although azithromycin MDA has been shown to be associated with decreased child mortal-
ity in Ethiopia [2], previous studies have not shown an association with nutritional status [14].
However, in the previous studies, azithromycin treatment was part of the Trachoma control
strategy and was given as a single dose (either once or annually) mainly to children above 1
year of age. In contrast, in our study, although azithromycin was given at a single dose to study
women during labour, it reached the infancy through the breast milk for at least 4 weeks [15].
In Malawi, adding azithromycin to the standard intermittent preventive treatment for malaria
control during pregnancy showed a reduction of childhood stunting [8].
Our intervention might have reduced the incidence of malnutrition by reducing chronic
gut inflammation which is common among African children. Alternatively it may have medi-
ated changes in the intestinal microbiome which persisted beyond the trial period. Our results
are in line with a systematic review which found that antibiotic use promotes linear growth
and weight gain in children in low and middle-income countries [4]. Because the azithromycin
arm in our study had lower bacterial carriage, our results are also consistent with the results of
a previous observational study conducted in India, which found that bacterial nasopharyngeal
carriage at the age of two months was associated with increased risk of malnutrition at 6
months [16].
Table 2. Characteristics of study participants at birth.
Characteristics of study children at birth Azithromycin (N = 226)
n (%)
Placebo (N = 239)
n (%)
p-value
Age at follow up (days) Mean (SD) 372.5 (18.4) 373.6(17.7) 0.486
Mother’s age (years) Mean (SD) 26.5(5.3) 26.6(4.9) 0.684
Birth weight (kg) Mean (SD) 3.1(0.5) 3.1(0.5) 0.172
Sex Female 118 (52.2) 112 (46.9) 0.266
Male 108 (47.8) 127 (53.1)
Ethnicity Madinka 92 (40.7) 109 (45.6) 0.490
Jola 45 (19.9) 35 (14.6)
Wollof 25 (11.1) 24 (10.0)
Other 64 (28.3) 71 (29.7)
Apgar score (1 minute)2 5–6 5 (2.2) 2 (0.8) 0.232
7–8 16 (7.1) 10 (4.2)
9–10 204 (90.7) 224 (94.9)
Multiple pregnancy No 224 (99.1) 229 (95.8) 0.037
Yes 2 (0.9) 10 (4.2)
Season of birth1 Dry 178 (78.8) 190 (79.5) 0.909
Rainy 48 (21.2) 49 (20.5)
1Rainy season June- October; Dry season November—May
2 n = 1 missing Apgar score in azithromycin arm and n = 3 missing score in placebo arm
https://doi.org/10.1371/journal.pone.0206348.t002
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Few children in our study had severe malnutrition (Z-scores<-3) and none had clinical
signs of severe malnutrition (peeling skin lesions or bilateral pedal oedema), probably reflect-
ing the good care that these children received during the trial follow-up. This is consistent
with the low mortality observed in the study between 2–12 months of age (1/3 of that expected
in The Gambia) [17], and with the low rate of hospitalization.
Table 3. Anthropometrical measurements for nutritional status by study group at the follow-up visit.
Mean (SD) Azithromycin (N = 226)
Mean (SD)
Placebo
(N = 239)
Mean (SD)
Age at follow-up (days) 372.47(18.39) 373.64(17.70)
Height (cm) 71.7(2.8) 71.7(3.0)
Weight (kg) 8.8(1.1) 8.8(1.2)
Head circumference (cm) 45.5(1.5) 45.4(1.6)
MUAC (cm) 14.4(1.1) 14.3(1.3)
Z-score <-2SD
N (%)
Azithromycin (N = 226)
n (%)
Placebo
(N = 239)
n (%)
RR(95%CI) p-value
WAZ1 <-2SD 16(7.1) 29(12.1) 0.58(0.33,1.04) 0.065
HAZ2 <-2SD 58(25.7) 76(31.8) 0.81(0.60,1.08) 0.144
BMI3-for-age <-2SD 3(1.3) 8(3.3) 0.40(0.11,1.48) 0.152
WHZ4 <-2SD 5(2.2) 8(3.3) 0.66(0.22,1.99) 0.458
MUAC5-for-age <-2SD 3(1.3) 15(6.3) 0.21(0.06,0.72) 0.006
Head circumference-for-age <-2SD 9(4.0) 9(3.8) 1.06(0.43,2.62) 0.904
Z-score <-3SD
N (%)
Azithromycin (N = 226)
n (%)
Placebo
(N = 239)
n (%)
RR(95%CI) p-value
WAZ1 <-3SD 3(1.3) 5(2.1) 0.63(0.15,2.62) 0.526
HAZ2 <-3SD 14(6.2) 18(7.5) 0.82(0.42,1.61) 0.569
BMI3-for-age <-3SD 0(0.0) 2(0.8) 0.00(NA,NA) 0.168
WHZ4 <-3SD 0(0.0) 2(0.8) 0.00(NA,NA) 0.168
MUAC5-for-age <-3SD 1(0.4) 2(0.8) 0.53(0.05,5.79) 0.596
Head circumference-for-age <-3SD 1(0.4) 3(1.3) 0.35(0.04,3.36) 0.343
1WAZ = Weight for age
2HAZ = Height for age
3BMI = Body mass index
4WHZ = Weight for height
5MUAC = mid-upper-arm circumference
https://doi.org/10.1371/journal.pone.0206348.t003
Table 4. Proxy signs for nutritional status by study arm.
Signs for Nutritional status Azithromycin (N = 224)
n (%)
Placebo
(N = 239)
n (%)
RR (95%CI) p-value
Peeling skin lesions 0(0) 0 (0) NA1 1
Bilateral pedal oedema 0 (0) 0 (0) NA1 1
Sparse hair distribution 11(4.9) 18(7.5) 0.65(0.31,1.35) 0.257
Loosely fitting clothing 4(1.8) 10(4.2) 0.43(0.14,1.34) 0.176
Loose or sparse hair distribution 15(6.7) 24(10.0) 0.67(0.36,1.24) 0.241
1NA = Not applicable
https://doi.org/10.1371/journal.pone.0206348.t004
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The study had a number of limitations. First, it was not powered to detect a difference in
malnutrition. Second, approximately 20% of participants from the main trial were older than
13 months at the time of the long term CSS and were not included. The reason for this decision
was that growth is strongly age-dependent and, as such, growth statistics are hard to interpret
unless they are restricted to a narrow age range. Third, we did not have the resources for addi-
tional visits and were therefore unable to take further anthropometric measurements, or col-
lect data on other important variables such as breast feeding practices. Instead we relied on
weight measurements recorded on the infant’s welfare card, which were sometimes missing, to
calculate growth curves.
Conclusions
Our results suggest a possible beneficial effect of giving azithromycin during labour on the risk
of infant malnutrition. However, our findings are not conclusive and may be attributable to
chance. Larger studies with closer follow-up are warranted to confirm whether the interven-
tion has any effect on nutritional status of the offspring beyond the neonatal period. These
studies should record the prevalence of antibiotic resistance as a potential drawback of the
intervention [10].
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